THE ROLE OF KCNJ11 GENE IN NEONATAL DIABETES


*Pediatrics Department, National Research Centre
**Clinical & Chemical Pathology Department, National Research Center
***Clinical & Chemical Pathology Department, Cairo University

OBJECTIVE

We are aiming to identify mutations in the KCNJ11 gene encoding Kir6.2 as a cause of PND in order to identify patients with this mutation and modify their treatment regimen since those patients show better glycemic control on oral hypoglycemics than on insulin.

METHODS

It is a prospective cross sectional observational study done after obtaining approval from the ethical committee. Written informed consent was obtained from patients or their parents after full discussion about the aim of the study.

Seventeen patients (age ranged from 1-16 years) were enrolled in this study, from the Diabetes Pediatric clinic of National Research Centre. They were previously diagnosed to have diabetes mellitus (DM) before the age of 2 years.

Exclusion criteria including: patients with transient neonatal diabetes, patients with syndromic diabetes.

-All patients were subjected to full history taking, general and neurological examination.

-Three ml of blood were collected from each subject in a sterile EDTA vacutainer for the genotyping technique. All samples were subjected to DNA extraction, purification and sequencing of KCNJ11 gene.

DNA was extracted from fresh samples or samples were stored at -80°C till DNA extraction.

Sequences were compared to the published sequence (NM_000525.3) using BLAST (Basic Local Alignment Search Tool) (www.ncbi.nlm.nih.gov) with nucleotide +1 corresponding to A of the ATG translation initiation codon of the reference sequence.

RESULTS

All of patients that got the E23EK polymorphism (total no. is 14) also got the I337V polymorphism.

The sequence result of PCR products of KCNJ11, E23K polymorphism G>A (67), I337V polymorphism G>A(1009), L270V polymorphism C>G(808), A190A mutation C>T(570).

CONCLUSIONS

In conclusion, our study identified a heterozygous activating KCNJ11 mutation (p.R201H) in a subject who was clinically misdiagnosed as type 1 diabetes diagnosed at the age of 1.5 months.

Sulfonylurea therapy proved to be effective in patients with activating KCNJ11 mutations. We recommend to screen patients presenting with diabetes in the first six months of life for mutation in KCNJ11. Long-term studies are needed to ensure the long-term safety and effectiveness of sulfonylureas.